-
公开(公告)号:US20230263949A1
公开(公告)日:2023-08-24
申请号:US18003071
申请日:2021-06-25
申请人: NXT Biomedical, LLC
发明人: Joseph Passman , Alexander Siegel , Glen Rabito , Stanton J. Rowe , Elliot Howard , Abubaker Khalifa , Robert C. Taft
CPC分类号: A61M1/3655 , A61B17/11 , A61B2017/1107 , A61F2250/0039
摘要: A variety of methods and devices for manipulating tissue using stents and shunts that foreshorten when expanded. Many of the devices have ends that expand radially more than a center portion of the device, creating an hourglass or rivet shape that is useful for anchoring the device or putting a squeezing force on the tissue.
-
公开(公告)号:US20220088355A1
公开(公告)日:2022-03-24
申请号:US17424840
申请日:2020-02-06
申请人: NXT Biomedical, LLC
发明人: Glen Rabito , Joseph Passman , Robert C. Taft , Stanton J. Rowe , Robert S. Schwartz , Alexander Siegel
IPC分类号: A61M27/00 , A61M60/165 , A61M60/216 , A61F2/82 , A61F2/24 , A61B17/00
摘要: Methods and devices that prevent stasis in the LAA by either increasing the flow through the LAA or by closing off or sealing the LAA. Increasing the flow is accomplished through shunts, flow diverters, agitators, or by increasing the size of the ostium. Closing off the LAA is accomplished using seals or by cinching the LAA.
-
3.
公开(公告)号:US20230320877A1
公开(公告)日:2023-10-12
申请号:US18334302
申请日:2023-06-13
申请人: NXT Biomedical, LLC
发明人: Robert S. Schwartz , Stanton J. Rowe , Robert C. Taft , Glen Rabito , Alexander Siegel , Joseph Passman
CPC分类号: A61F2/958 , A61F2/82 , A61F2/9522
摘要: Devices and methods of treating conditions cause or exacerbated by excessive fluid pressures or retentions, such as pulmonary hypertension, that involves shunting excessive fluid pressure from one bodily chamber or vessel to another bodily chamber or vessel.
-
公开(公告)号:US11717429B2
公开(公告)日:2023-08-08
申请号:US16576704
申请日:2019-09-19
申请人: NXT Biomedical, LLC
发明人: Robert S. Schwartz , Stanton J. Rowe , Robert C. Taft , Glen Rabito , Alexander Siegel , Joseph Passman
CPC分类号: A61F2/958 , A61F2/82 , A61F2/9522
摘要: Devices and methods of treating conditions cause or exacerbated by excessive fluid pressures or retentions, such as pulmonary hypertension, that involves shunting excessive fluid pressure from one bodily chamber or vessel to another bodily chamber or vessel.
-
公开(公告)号:US11559672B2
公开(公告)日:2023-01-24
申请号:US17662413
申请日:2022-05-06
申请人: NXT Biomedical, LLC
发明人: Glen Rabito , Joseph Passman , Robert C. Taft , Stanton J. Rowe , Robert S. Schwartz , Alexander Siegel
IPC分类号: A61M27/00 , A61M60/165 , A61M60/216 , A61B17/00 , A61F2/24 , A61F2/82 , A61M60/161 , A61M60/289 , A61M60/861
摘要: Methods and devices that prevent stasis in the LAA by either increasing the flow through the LAA or by closing off or sealing the LAA. Increasing the flow is accomplished through shunts, flow diverters, agitators, or by increasing the size of the ostium. Closing off the LAA is accomplished using seals or by cinching the LAA.
-
公开(公告)号:US20220257221A1
公开(公告)日:2022-08-18
申请号:US17597857
申请日:2020-07-29
申请人: NXT Biomedical, LLC
发明人: Stanton J. Rowe , Robert S. Schwartz , Elliot Howard , Robert C. Taft , Alexander Siegel , Joseph Passman , Glen Rabito , Abubaker Khalifa
摘要: Low profile biopsy tools and methods that allow relatively large biopsy samples to be taken. The biopsy tools have a first configuration that allows for atraumatic navigation to a targeted lesion, and a second configuration in which a distal end of the biopsy tool expands to take a large tissue sample. The tissue sample may then be retracted into a sheath or other containment feature and removed at a reduced diameter. Also included is an anchored guidewire usable to practice method for navigating a biopsy tool to a targeted lesion after an endoscope has been removed.
-
公开(公告)号:US20220176087A1
公开(公告)日:2022-06-09
申请号:US17652468
申请日:2022-02-24
申请人: NXT Biomedical, LLC
发明人: Robert S. Schwartz , Stanton J. Rowe , Alexander Siegel , Joseph Passman , Robert C. Taft , Glen Rabito
摘要: Devices and methods of treating fluid retention caused by congestive heart failure or other conditions resulting in edema, lymphoedema, or significant fluid retention (e.g., deep vein thrombosis, cellulitis, venous stasis insufficiency, or damage to the lymphatic network) are described. Specifically, a treatment device is used to create a passage or cannula between the lymphatic system (or other area of the body) and an external drainage device. This device can be only temporarily located in the patient or can be implanted within the patient for longer periods of time. The physician can safely and reliably remove excess fluid from the body via the device and optionally inject other treatment agents.
-
公开(公告)号:US20230042304A1
公开(公告)日:2023-02-09
申请号:US17759172
申请日:2021-01-15
申请人: NXT Biomedical, LLC
发明人: Jeremy Koehler , Elliot Howard , Abubaker Khalifa , Joseph Passman , Glen Rabito , Stanton J. Rowe , Alexander Siegel , Robert S. Schwartz , Robert C. Taft
摘要: Several embodiments and methods are described for draining a lymphatic system for therapeutic purposes. The lymphatic draining can be performed by removal of fluid from the lymphatic system via a needle, a catheter, an access port, a reservoir, a shunt, or a combination of these devices. The drainage devices can be configured for use during only a single procedure or for reoccurring procedures.
-
公开(公告)号:US20220355085A1
公开(公告)日:2022-11-10
申请号:US17814220
申请日:2022-07-21
申请人: NXT Biomedical, LLC
IPC分类号: A61M25/10 , A61M60/833 , A61M60/135 , A61M60/33 , A61M60/216
摘要: Several embodiments of a catheter are described, having a balloon configured to slowly inflate and then quickly deflate to create an area of low pressure in the vessels. The balloon can be cycled near the vessels of the kidneys, thereby helping to draw out blood from the kidneys and enhance fluid processing to the bladder.
-
公开(公告)号:US20220142806A1
公开(公告)日:2022-05-12
申请号:US17595386
申请日:2020-05-18
申请人: NXT Biomedical, LLC
发明人: Joseph Passman , Abubaker Khalifa , Stanton J. Rowe , Glen Rabito , Robert C. Taft , Alexander Siegel
摘要: Renal and urine collection system interventions are provided that improve kidney function by manipulating pressures and/or infusing therapeutic agents in the renal pelvis of the kidney or kidneys. Setting a vacuum and/or infusing therapeutic agents in the renal pelvis results in increased glomerular filtration rate, general solute clearance, and free water excretion via the kidney through the urinary tract and is useful for treatment of CHF, ADHF, AKI, CKD, and many other conditions characterized by fluid overload by reducing fluid buildup. The fluid drawn from the renal pelvis or pelvises is delivered to an external or implanted reservoir or to the bladder using flow manipulation mechanism such as one-way valves, occlusion balloons, multi-lumen catheters, and other mechanisms. Pumps are provided for use in establishing the vacuum pressures that are either manual or motorized.
-
-
-
-
-
-
-
-
-